Amy Barton Pai, Pharm.D., BCPS, FASN, FCCP, FNKF
Amy Barton Pai
Work Address
University of MichiganCollege of Pharmacy
428 Church Street
Pharm 3056
Ann Arbor, MI 48109
PERSONAL INFORMATION
Date of BirthMay 25, 1973
Place of BirthRhinebeck, NY
CitizenshipUnited States
FACULTY APPOINTMENTS
July 2016-presentAssociate Professor with Tenure
College of Pharmacy, Department of Clinical Pharmacy
University of Michigan
Ann Arbor, MI
Sept 2015-May 2016Chair
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York
October 2014-June 2016Professor with Tenure
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York
October 2008-October 2014Associate Professor
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York
July 2010-June 2016Adjunct Associate Professor of Internal Medicine
Division of Nephrology and Hypertension
Albany Medical College
Albany, New York
July 2007-September 2008Associate Professor of Pharmacy and Nephrology with Tenure
University of New Mexico
College of Pharmacy and School of Medicine
Albuquerque, New Mexico
August 2001-June 2007Assistant Professor of Pharmacy and Nephrology
University of New Mexico
College of Pharmacy and School of Medicine
Albuquerque, New Mexico
EDUCATION
2015-presentArizona State University
Master’s in Healthcare Innovation
1997-1999Albany College of Pharmacy, Albany, New York Doctor of Pharmacy, magna cum laude
1993-1996Albany College of Pharmacy, Albany, New York
Bachelor of Science in Pharmacy, cum laude
1991-1993Dutchess Community College, Poughkeepsie, New York
Chemistry major
CERTIFICATION
December 2003Board Certified Pharmacotherapy Specialist
Re-certified 2010
April 2012Medication Therapy Management
LICENSURE
1996New York- 044397
1999Illinois- 051-287158 (inactive)
2001New Mexico- RP00006435 (inactive)
2016Michigan 5302045267
RESIDENCY/FELLOWSHIP EXPERIENCE
1999-2001Nephrology Fellowship
University of Illinois at Chicago, Chicago, IL
Mentor: Alan Lau, Pharm.D.
1996-1997Pharmacy Practice Residency
St. Peter’s Hospital, Albany, New York
Residency Director: Thomas Lombardi, Pharm.D.
1
Amy Barton Pai, Pharm.D.
PROFESSIONAL EXPERIENCE
1997-1998Relief Pharmacist
Price Chopper Pharmacy Albany, New York
1996-1999Per Diem Staff Pharmacist
St. Peter’s Hospital Albany, New York
1993-1996Pharmacy Intern/Pharmacist
Red Hook Drug Store, Red Hook, New York
1993-1995On-Line Service Representative
Pharmacy Service Corporation of New York, Albany, New York
1989-1993Pharmacy Technician
CVS Pharmacy, Hyde Park, New York
1
Amy Barton Pai, Pharm.D., BCPS, FASN, FCCP, FNKF
CLINICAL SERVICE
Oct 2016-presentNephrology Pharmacotherapy Specialist
University of Michigan Outpatient Hemodialysis
Ann Arbor, NY
Oct 2014-Jul 2016Nephrology Pharmacotherapy Specialist
Transitions in Care Program
Dialysis Clinic Inc, Capital Region Network
Saratoga, Clifton Park, Troy, NY
June 2011-Oct 2014Nephrology Pharmacotherapy Specialist
Rubin Dialysis/MyMedZ MTM service
Troy, NY
Aug 2010-Jan 2013Nephrology Pharmacotherapy Specialist
Renal Consult Service
Albany Medical Center Hospital, Albany, NY
Feb 2009-May 2011Albany Regional Kidney Center
Hemodialysis Unit
Provide pharmaceutical care to 180 patients
Dec 2004-Oct 2008Nephrology Pharmacotherapy Specialist
University of New Mexico Chronic Kidney Disease (CKD) clinic
Triage patients, recommend optimal therapies, screen for anemia and secondary hyperparathyroidism.
Aug 2001-Oct 2008Nephrology Pharmacotherapy Specialist
Dialysis Clinic, Inc. outpatient hemodialysis unit, Albuquerque, NM
Provide pharmaceutical care to 175 patients, participate in weekly and monthly rounds, initiate and revise drug policy and procedures, provide inservices to staff.
PUBLICATIONS
Original Research
Pai AB, Garba A, Prokopienko A, Neumann P, Narsipur S,. Quantification of Lipoteichoic Acid in Dialysis Patients with Central Venous Catheters. (Submitted: Plos One)
Pai AB, Meyer D, Bales B, Cotero V, Pai MP, Zheng N, Jiang W. Performance of redox active and chelatable iron assays to determine labile iron release for intravenous iron formulations. (Accepted: Clin Trans Sci)
Pai AB, Grabe DW, Eisele G, Patel H, Kubotera S, Prokopienko A, Nolin T. Changes in plasma levels of asymmetric dimethylarginine in chronic kidney disease patients treated for 8 weeks with the vitamin D receptor agonist paricalcitol. J Res Development. 2015;3:2
Jang S, Prokopienko AJ, Grabe DW, Cerulli J, Fox C, Vassalotti J, Pai AB.NSAID-Avoidance Education in Community Pharmacies for Patients at High Risk for Acute Kidney Injury, Upstate New York, 2011. Prev Chronic Dis. 2014 Dec 18;11:E220PMID:25523351
Asif A, Carrillo R, Garisto JD, Monrroy M, Khan RA, Castro H, Merrill D, Ali AS, Pai AB, Waldman J, Salman L. Prevalence of Chronic Kidney Disease in Patients Undergoing Cardiac Rhythm Device Removal. Semin Dial. Semin Dial. 2013 Jan-Feb;26(1):111-3 PMID: 22780814
Pai AB, Patel H, Prokopienko A, Gertzberg N, Alsaffar H, Neumann P, Punjabi A, Johnson A. Lipoteichoic acid from Staphylococcus aureus induces lung endothelial cell barrier dysfunction: role of reactive oxygen and nitrogen species. Plos One 2012;7(11):e49209PMID: 23166614
Conner TA, McQuade CR, Olp J, Pai AB. Effect of Intravenous Vitamin C on Reactive Oxygen Species Generation, Cytokine Activation and Oxidative Stress in Hemodialysis (HD) Patients Receiving Intravenous Iron Sucrose (IS). Biometals. 2012 Oct;25(5):961-9 PMID: 22706571
Pai AB. Feleder C, Johnson A. Tumor Necrosis Factor-α (TNF) induces increased lung vascular permeability: a role for GSK3α/b. Eur J Pharmacol. 2011 Apr 25;657(1-3):159-66 PMID: 21316358
Pai AB, McQuade C, Olp J. Hicks P, Conner T. Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). Biometals. 2011 Aug;24(4):603-13PMID: 21229380
Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai AB. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrology 2010:11;16 PMID: 20716362
Pai AB, Nielson JC, Kausz A, Miller P, Owen J. Plasma Pharmacokinetics of two consecutive doses of ferumoxytol in Healthy Subjects. Clin Pharmacol Ther 2010;June 30:1-5 PMID: 20592725
Pai AB, Depczynski JC, Martinez I, Boyd A, Khan N, Manley HJ. Reduced Drug Use Hospitalization Rates in Patients Undergoing Hemodialysis Who Received Pharmaceutical Care-a 2 year randomized, controlled study. Pharmacotherapy 2009;29(12):1433-1440 PMID: 19947803
Demirovic J, Pai AB, Pai MP. Creatinine Clearance Estimation in Morbidly Obese Patients. Am J Health Syst Pharm 2009;66(7)642-648 PMID: 19299371
Boyd A, McQuade CR, Conner TA, Manley HJ, Pai AB. Correlation between the Renal Quality of Life Profile (RQLP) and Short Form−36 (SF−36) in a United States (US) Hemodialysis (HD) Population. Letter. Hemodial Int 2009;89-90 PMID: 19210284
Pai AB, Boyd A, Chavez A, Manley HJ. Health-related Quality of Life is Maintained in Hemodialysis Patients Receiving Pharmaceutical Care-A 2-Year Randomized, Controlled Study. Hemodial Int; 2009;13:72-79 PMID: 19210281
Pai AB, Norenberg JP, Boyd A, Raj DSC, Chan L. Intravenous Iron is Associated with Increased Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients. Clin Ther 2007;29:2699-2705 PMID: 18201586
Pai AB, Harford A, Boyd AV, McQuade C, Norenberg JP, Zager P. Comparison of oxidative stress markers in hemodialysis patients following administration of iron dextran, sodium ferric gluconate and iron sucrose. Pharmacotherapy 2007;27:343-350.PMID: 17316146
Boyd AV, Townsend K, Dunne A, Spalding CT Pai AB. Optimal sampling for international normalized ratios in hemodialysis patients with central venous catheters. Nephrol Nurs J 2006;33:408 PMID: 17001998
Pai AB, Depczynski J, Pai MP, McQuade C, Mercier RC. Non‑transferrin bound iron is associated with enhanced staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol 2006;26:304‑309 PMID: 16809897
Raj DSC, Dominic EA, Pai A, Osman F, Morgan M, Pickett G, Shah VO, Ferrando A, Moseley P: Skeletal muscle, cytokines and oxidative stress in End-stage renal disease. Kidney Int 2005;68:2338-2344 PMID: 16221238
Pai AB, Pai MP. A limited sampling algorithm for vancomycin dosing during hi-flux hemodialysis. Am J Health Syst Pharm 2004;61:1812-6 PMID: 15462252
Pai AB, Lin S, Arruda J, Lau AH. Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients. Int J Artif Organs 2003;26(6):484-90 PMID: 12866654
Pai AB, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients Clinical Nephrology 2002;58:38-46 PMID: 12141405
Barton AE, Levin GM. Evaluating the incidence of antidepressant-induced sexual dysfunction Hospital Pharmacy 2000 Jun:35(6);609-613
1
Amy Barton Pai, Pharm.D., BCPS, FASN, FCCP, FNKF.
Case Reports
McQuade CM, Griego J, Anderson J, Pai AB. Dose-dependent elevation in serum creatinine associated with fenofibrate therapy. Am J Health Syst Pharm. 2008;65:138-41 PMID: 18192258
Carson J, Gold L, Barton A, Biss R. Fatality and interferon alpha for malignant melanoma. Lancet (letter) 1998 Oct 31; 352(9138): 1443-4 PMID: 9807998
Barton A Burns, Bailie GR, Eisele G, McGoldrick D, Rosano TG, Swift T. Use of pharmacokinetics to determine the duration of dialysis in management of methanol poisoning Am J Emerg Med. 1998 Sep;16(5):538-40 PMID: 9725978
Review Articles and Editorials
Pai AB, Teoh B, Cardone K. Expanding the Role of Pharmacy Technician: Value to Provision of Medication Management Services in Hemodialysis Units. (Submitted: Journal of Pharmacy Practice)
Pai AB, It’s all about ADME. Adv in Chronic Kidney Dis. 2016 Mar;23(2):76-81
Schwenk M., Pai AB.Drug Transporter Function-Implications in Chronic Kidney Disease. Adv in Chronic Kidney Dis. 2016 Mar;23(2):61-2
Gilmartin C, Pai AB, Hughes D, Hilal N. Risky business: Lessons from medication misadventures in chronic kidney disease.Physician Assist Clinic 2016;1:55-76
Pai AB, Jang S, Wegryzn N. Iron-based Phosphate Binders-A New Element for Treatment of Hyperphosphatemia in Kidney Disease. Expert Opin. Metab. Toxicol.. 2016 Jan;12(1):115-27
Pai AB. Keeping Kidneys Safe: The Pharmacist’s Role in NSAID Avoidance in High-Risk Patients. J Am Pharm Assoc (2003). 2015 Jan 1;55(1):e15-25PMID:25503987
Pai AB. Evaluating Plasma Pharmacokinetics of IV Iron Formulations: Judging Books by Their Covers? Clin Pharmacokinet2015:54(4);323-4
Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, On behalf of the American Society of Nephrology Dialysis Advisory Group.Considerations and Challenges in Defining the Optimal Utilization of Iron in Dialysis-Dependent Chronic Kidney Disease. Invited Commentary, J Am Soc Nephrol. 2015;26(6):1238-1247 PMID:25542967
Manley HJ, Pai AB. Integrated Pharmacy Services: a necessary component for ESRD patient care. Am J Kidney Dis 2013; Sep;62(3):445-7 PMID: 23972057
Pai AB, CardoneKE, ManleyHJ, St. PeterW,ShafferR, SomersM, MehrotraR.Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients: Need for a Systematic Approach. Clin J Am Soc Nephrol. Invited Commentary. 2013 Nov;8(11):1988-99 PMID: 23990162
Pai AB, Garba AO. Ferumoxytol: a silver lining in thetreatment of anemia of chronic kidney disease: or another dark cloud?Journal of Blood Medicine 2012;3:77-85PMID: 22973119
Kubotera N, Prokopienko A, Garba AO, Pai AB. Endotoxin Binding by Sevelamer:Potential Impact on Nutritional Status. Int J Nephrol. 2013;2013:954956. PMID: 23401772
Moore CL, Pai AB. CKD: Pharmacotherapy in a House of Mirrors. (editorial) Adv in Chronic Kidney Dis. 2010;17:381-83 PMID: 20727507
Cardone KE, Bacchus S, Assimon M, Pai AB, Manley HJ. Medication-Related Problems in Chronic Kidney Disease. Adv in Chronic Kidney Dis 2010;17:404-412 PMID: 20727510
Assimon M, Mousa S, Shaker O, Pai AB.The Effect of Sevelamer Hydrochloride and Calcium Based Phosphate Binders on Mortality in Hemodialysis Patients: A Need for More Research. Consultant Pharm. 2010;35:37-51PMID: 20211816
Pai AB, Conner TA, McQuade CR. Therapeutic Use of the phosphate binder Lanthanum Carbonate. Expert Opin Drug Metab and Toxicol 2009; 5 (1):71-81 PMID: 19236230
Pai AB, Conner TA. Oxidative Stress and Inflammation in Chronic Kidney Disease: Role of Intravenous Iron and Vitamin D. J Pharm Prac 2008;21:214-224
Pai AB. Broader Roles of Vitamin D in Patients with Chronic Kidney Disease. Kidney: A Current Survey of World Literature. 2006;15:199-201
Pai AB, Pai MP. Optimizing Antimicrobial Therapy for Gram-positive Bloodstream Infections in Patients on Hemodialysis. Adv in CKD 2006; Jul;13(3):259-70 PMID: 16815231
Martinez I, Pai AB. Use of antibiotic lock solutions in hemodialysis catheter-related bloodstream infections. Kidney: A Current Survey of World Literature. 2005;14:53-56
Pai AB, Smeeding JE, Brook RA. The role of sevelamer in achieving the kidney disease outcome quality initiative (K/DOQI) for hyperphosphatemia. Curr Med Res Opin. 2004;20:991-999 PMID: 15265243
Pai AB. Intravenous iron and bacteremia in hemodialysis patients. Kidney: A Current Survey of World Literature. 2004;13:51-53
Pai AB. Warfarin for prevention of vascular access thrombosis in hemodialysis patients. Kidney: A Current Survey of World Literature. 2003;12:201-203
Pai AB. Iron and oxidative stress. Kidney: A Current Survey of World Literature. 2003;12:53-56
1
Amy Barton Pai, Pharm.D., BCPS, FASN, FCCP, FNKF
Smith HS, Barton AE. Tizanidine in management of spasticity and musculoskeletal complaints in the palliative care population. American Journal of Hospice and Palliative Care 2000 Jan/Feb:17(1);50-58 PMID: 11094920
ABSTRACTS
Pai AB, Polanco N, Garfinkel M, Mansour V. Assessing literacy skills related to NSAID medication labeling in primary care. American Society of Nephrology Kidney Week; November 19, 2016, Chicago, IL
Pai AB, Meyer D, Bales B, Cotero V, Pai MP. Labile iron release from intravenous iron formulation: considerations for bioequivalence. Global Summit on Regulatory Science: Nanotechnology Standards and Applications. National Institutes of Health, Bethesda, MD, September 12, 2016
Wegrzyn NM, Parker WM, Pai AB, Daoui R, Daoui S, Cardone KE. Assessing health literacy in outpatient nephrology patients. Abstract accepted: National Kidney Foundation Spring Clinical Meeting; April 28, 2016, Boston, MA.
Raouf M, Kelsey T, Wilming C, Cabral K, LaFleur C, Pai AB.A student pharmacist-led public health initiative for early identification of cardiovascular and kidney disease risk factors. American College of Clinical Pharmacy Global Conference, October 19, 2015, San Francisco, CA.
Pai AB, Meyer D, Bales B, Cotero V, Pai A, Zheng N, Jiang W.Labile Iron Release From Intravenous (IV) Iron Formulations: Considerations For Bioequivalence. National Kidney Foundation Spring Clinical Meeting. March 27, 2015
Pai AB, Cardone K, Daoui R, Salenger P, Chen X, Kao T, Boverman G, Davenport D.
Utility Of Bioelectrical Impedance Spectroscopy (BIS) With Electrical Impedance Tomography (Eit) To Evaluate Regional Volume Flux In Hemodialysis (HD) Patients.National Kidney Foundation Spring Clinical Meeting. March 27, 2015
Pai AB, Narsipur S, Goldstein L.Lipoteichoic Acid As A Non-Invasive Marker Of Biofilm Burden In Hemodialysis (HD) Patients. National Kidney Foundation Spring Clinical Meeting. March 27, 2015
Pai AB, Meyer D, Bales B, Cotero V, Pai M, Zheng N, Jiang W.Performance of redox active and chelatable iron assays to determine labile iron concentrations from intravenous iron formulations. Innovation@CDER, Center for Drug Evaluation and Research, September 10, 2014, Silver Spring, MD
Assessing Literacy and Numeracy Skills Relating to Medication Labeling in Patients on Dialysis. Cho S, Parker W, Teoh B, Pai AB, Cardone KE. National Kidney Foundation Spring Clinical Meeting. Las Vegas, NV April 23, 2014
Pai AB, Garba AO, Waldman J. A Non-Invasive Approach to Evaluation of Biofilm Burden in Hemodialysis Patients. American Society of Nephrology Renal Week. November 6, 2013. Atlanta, GA
Peres de Alcantara D, Prokopienko AJ, Cardone K,Pai AB. Medication Management Services for Dialysis Patients in Brazil-A Survey of Clinicians. American College of Clinical Pharmacy, October 14, 2013, Albuquerque, NM.
Prokopienko A, Lawuyi A, Gertzberg N, Neumann P, Johnson A, Pai AB. Differential Effect of IV Iron Compounds on Intracellular Labile Iron Pool in Aortic Coronary Endothelial Cells. American College of Clinical Pharmacology. Bethesda, MD. September 20, 2013.
Cardone KE, Parker W, Pai AB, Cavanaugh K. Assessment of medication label literacy and numeracy skills in hemodialysis patients. National Kidney Foundation 2013 Spring Clinical Meeting, April 2-6, 2013; Orlando, FL. Poster #117; Poster presentation.
Patel H. Kubotera N, Prokopienko A. Cardone KE, Pai AB. Usage of Erythropoiesis Stimulating Agents Pre and Post Bundle. American Society of Health-systems Pharmacists Mid-Year Clinical Meeting, December 7, 2011, New Orleans, LA
Patel HV, Prokopienko AJ, Gertzberg N, Neumann P, Johnson A, Pai AB. Differential Effect of IV Iron Compounds on Intracellular Reactive Oxygen Species (ROS) Generation in Aortic Coronary Endothelial Cells. American College of Clinical Pharmacy Annual Meeting (Best Student Paper Finalist). October 17, 2011, Pittsburgh, PA
Cardone KE, Fox B, Meola S, Goldstein L, Hoy C, Salenger P, Pai AB. Effects of the ESRD Medicare Bundling Rule on Anemia Management in Private Dialysis Units. American Society of Nephrology Renal Week. November 11, 2011, Philadelphia, PA
Pai AB, Grabe DW, Eisele G. Effect of the Vitamin D receptor Agonist Paricalcitol on Cell Adhesion Markers and ADMA in CKD 3 and 4. ERA-EDTA Annual Meeting, June 24, 2011, Prague, Czech Republic
Sidile J, Der Mesorpian P, Makary Y, Pai AB, Haqqie S. Evaluation of Predictive Factors of Potassium Derangement in Therapeutic Hypothermia. National Kidney Foundation, Spring Clinical Meeting. April 27, 2011, Las Vegas, NV
Pai AB, Johnson A, Role of Intravenous Iron Compounds in Pathogenesis of Pulmonary Edema. ASN Renal Week, November 17-21, 2010, Denver, CO
Pai AB, Johnson A. Lipoteichoic Acid (LTA) Induced Lung Endothelial Barrier Dysfunction: Possible Role of Endothelial Nitric Oxide (eNOS). ASN Renal Week, November 17-21, 2010, Denver, CO
Pai AB, Grabe DW, Eisele G. Effect of the Vitamin D receptor Agonist Paricalcitol on Biomarkers of Vascular Reactivity in CKD 3 and 4. ASN Renal Week, November 17-21, 2010, Denver, CO
Johnson A, Pai A. Lipotechoic acid (LTA) causes reactive oxygen species dependent lung endothelial barrier dysfunction. American Thoracic Society, May 17, 2010, New Orleans, LA
Pai AB, Gertzberg N, Neumann P, Johnson A. Role of Lipotechoic acid from Staphylococcus aureus in Pathogenesis of Pulmonary Edema. ASN Renal Week, October 30, 2009, San Diego, CA
Conner T, Raj D, McQuade C, Olp J, Pai AB, Effect of Intravenous Ascorbic Acid on Cytokine Activation and Oxidative Stress in Hemodialysis (HD) Patients Receiving Intravenous Iron Sucrose (IS). ASN Renal Week, November 6, 2008, Philadelphia, PA
Pai AB, Raj D, McQuade C, Olp J. Hicks P, Conner T. Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). ASN Renal Week, November 6, 2008, Philadelphia, PA
Pai AB, Owen J, Clarkin M, Nielson J, Clark T. Lawler D, Kausz A. Plasma Pharmacokinetic (PK) Profile of Ferumoxytol in Healthy Subjects. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA
Boyd A, McQuade CR, Manley HJ, Pai AB. Correlation between the Renal Quality of Life Profile (RQLP) and Short Form−36 (SF−36) in a United States(US) Hemodialysis (HD) Population. Abstract SU−PO1099. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA
Demirovic J, Pai AB, Conner TC, Pai M. Comparison of Nafcillin and Cefazolin for Methicillin Sensitive Staphylococcus aureus (MSSA)Related Bloodstream Infections (BSI) in Hemodialysis (HD) Patients. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA
McQuade CR, Boyd AV, Conner T, Pai AB. Clinical pharmacy research training program (CPRTP): a longitudinal approach to career development. Abstract # 268. Annual Meeting of the American College of Clinical Pharmacy. October 16, 2007. Denver, CO
Pai AB, Norenberg JP, Boyd AV, Raj DSC, MD,Chan L, Intravenous Iron is Associated with Increased Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients J Am Soc Nephrol 2006;17:481A
Horton E, Pai AB, Anselmo L, Garcia D. Case-control analysis of prophylactic enoxaparin therapy in obese patients. American College of Clinical Pharmacy, October 28, 2006 St. Louis, MO
McQuade C, Boyd A, Chavez A, Burke R, Pai AB. Factors associated with hypocalcemia in hemodialysis patients receiving cinacalcet HCL for secondary hyperparathyroidism.American College of Clinical Pharmacy, October 29, 2006 St. Louis, MO
Pai AB, Depczynski JC, Martinez I, Boyd A, Chavez A, Manley HJ. Impact of Clinical Pharmacy Services on Medication Costs, Hospitalization Rates and Drug-Related Problems in Hemodialysis (HD) Patients. J Am Soc Nephrol 2005;16:725A